Comparative Pharmacology
Head-to-head clinical analysis: ALUPENT versus BRETHAIRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUPENT versus BRETHAIRE.
ALUPENT vs BRETHAIRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle, leading to bronchodilation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Inhalation: 2 inhalations (0.65 mg per inhalation) every 3-4 hours, up to 12 inhalations per day. Oral: 20 mg three to four times daily.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
None Documented
None Documented
The terminal elimination half-life of metaproterenol (Alupent) is approximately 2.5–5 hours after oral administration, and 2–4 hours after intravenous or inhaled routes. Its relatively short half-life supports dosing every 4–6 hours for bronchodilator effect.
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
Renal excretion of unchanged drug and metabolites accounts for approximately 40-60% of the dose, with the remainder eliminated via biliary/fecal routes. Following oral administration, about 30-40% is recovered in urine as unchanged drug and glucuronide conjugates, and 50-60% in feces. After intravenous administration, renal elimination is 40-50% unchanged, with biliary excretion contributing 30-40%.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist